Danaher Co. (NYSE:DHR) Shares Sold by Ballentine Partners LLC

Ballentine Partners LLC lowered its position in shares of Danaher Co. (NYSE:DHR) by 1.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 17,769 shares of the conglomerate’s stock after selling 194 shares during the quarter. Ballentine Partners LLC’s holdings in Danaher were worth $4,940,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Tsfg LLC raised its position in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher during the second quarter valued at $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher during the second quarter worth $25,000. Redmont Wealth Advisors LLC bought a new position in shares of Danaher in the 1st quarter worth about $30,000. Finally, MFA Wealth Advisors LLC acquired a new position in shares of Danaher in the 2nd quarter valued at about $51,000. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,059 shares of company stock worth $8,400,897 in the last ninety days. 11.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on DHR shares. Bank of America increased their price objective on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Leerink Partners raised their price target on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Robert W. Baird lowered their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday. TD Cowen increased their target price on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Raymond James reduced their price target on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $287.28.

Danaher Price Performance

Shares of NYSE:DHR opened at $247.88 on Friday. The stock has a market cap of $183.60 billion, a price-to-earnings ratio of 42.01, a PEG ratio of 4.49 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The stock’s 50 day moving average price is $270.43 and its 200 day moving average price is $260.43.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the previous year, the business earned $2.02 EPS. The company’s quarterly revenue was up 3.1% compared to the same quarter last year. Equities research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.